Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Anticancer Drugs
; 35(5): 418-425, 2024 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-38386011
ABSTRACT
The clinical significance of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) for non-small cell lung cancer (NSCLC) treated with the combination of anti-angiogenic therapy and anti-PD-L1 antibody (Ab) remain unknown. This study aimed to explore the association between plasma sPD-L1 and VEGF levels and the prognosis of NSCLC patients treated with the combination of Envafolimab and Endostar. Peripheral blood samples were collected from 24 NSCLC patients at baseline and after 6 weeks of treatment and were detected for sPD-L1 and VEGF levels. Both baseline and posttreatment sPD-L1 were significantly higher in progressive disease (PD) group than in controlled disease (CD) group (median 77.5 pg/ml vs. 64.6 pg/ml, P â
=â
0.036, median 8451 pg/ml vs. 5563 pg/ml, P â
=â
0.012). In multivariate analysis, lower baseline sPD-L1 levels were significantly associated with longer progression-free survival (PFS) (HRâ
=â
6.834, 95% CI 1.350-34.592, P â
=â
0.020). There were significantly higher posttreatment VEGF levels in PD group compared with CD group (median 323.7 pg/ml vs. 178.5 pg/ml, P â
=â
0.009). Higher posttreatment VEGF levels were significantly associated with shorter PFS in multivariate analysis (HRâ
=â
5.911, 95% CI 1.391-25.122, P â
=â
0.016). Plasma sPD-L1 and VEGF levels are associated with the clinical response and prognosis of NSCLC patients treated with the combination of PD-L1 inhibitors and anti-angiogenetic therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Fator A de Crescimento do Endotélio Vascular
/
Antígeno B7-H1
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Revista:
Anti-cancer drugs
/
Anticancer Drugs
/
Anticancer drugs
Assunto da revista:
ANTINEOPLASICOS
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China